Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
604 Results for "
SCO2 mutations
" in MedChemExpress (MCE) Product Catalog:
Products (604)
604 Results for "SCO2 mutations" in MCE Product Catalog:
Cat. No.: HY-137849
CAS No.: 2171388-28-4
RK-582 is a tankyrase inhibitor, antitumor agent, and orally bioavailable growth inhibitor, with an IC50 of 36.1 nM against human tankyrase-1 and an IC50 of 39.2 nM against human tankyrase-2. In APC-mutated colorectal cancer cells, the sensitivity to RK-582 correlates with the level of active β-catenin, while drug resistance associates with PIK3CA mutation. RK-582 can be used for the research of colorectal cancer [2].
Cat. No.: HY-148302
CAS No.: 1207456-03-8
LT-626 is a potent PARP inhibitor with an IC50 of 1.60 nM. LT-626 inhibits cellular PAR synthesis with an EC50 of 17.9 nM and shows enhanced cytotoxicity in colorectal cancer cells harboring MRE11 mutations. LT-626 exhibits synergistic effects with Cisplatin (HY-17394), Oxaliplatin (HY-17371), and SN-38 (HY-13704) in colorectal cancer cells. LT-626 can be used for colorectal research .
Cat. No.: HY-149802
CAS No.: 307552-53-0
Target:
Research Areas:
SLC26A3-IN-1 is an inhibitor of anion exchanger protein SLC26A3 (IC50=340 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea .
Cat. No.: HY-156167
CAS No.: 2704562-80-9
Target:
Research Areas:
LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant G2019S-LRRK2 kinase inhibitor with IC50s of 11 nM and 5.2 nM for G2019S-LRRK2 pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research .
Cat. No.: HY-164807
CAS No.: 1489236-55-6
Target:
Research Areas:
SARD279 is a HyT degrader of androgen receptor (AR). SARD279 binds to AR, recruits HSP70, mediates ubiquitin-dependent proteasomal degradation, and competitively inhibits the transactivation of AR. SARD279 exhibits antiproliferative activity in AR-dependent prostate cancer cells and castration-resistant prostate cancer cells, including those harboring the AR F876L mutation. SARD279 can be used in studies related to prostate cancer and castration-resistant prostate cancer [2] .
Cat. No.: HY-167710
CAS No.: 941185-83-7
Target:
Research Areas:
CRCD2 is a small molecule NT5C2 nucleotidase inhibitor with enhanced 6-mercaptopurine cytotoxic activity. CRCD2 can effectively reverse 6-mercaptopurine resistance caused by mutations in the NT5C2 gene or non-genetic activation mechanisms. CRCD2 combined with 6-mercaptopurine can enhance its cytotoxic activity in NT5C2 wild-type leukemia, showing its potential in the treatment of acute lymphoblastic leukemia .
Cat. No.: HY-174303
Target:
Research Areas:
NNRT-IN-9 (Compound EG28) is a non-nucleoside reverse transcriptase (NNRT) inhibitor. NNRT-IN-9 has potent antiviral and anti-resistance activity against wild-type (WT) HIV-1 and various clinically relevant mutations (E138K and K103N + Y181C) with EC50s of 55, 67 and 3910 nM, respectively. NNRT-IN-9 can be used for acquired immune deficiency syndrome (AIDS) research .
Cat. No.: HY-178215
CAS No.: 3099581-65-1
BRM/BRG1 ligand 4 (Compound 6) is a SMARCA2/4 PROTAC degrader. BRM/BRG1 ligand 4 exhibits potent degradation activity against both SMARCA2 and SMARCA4 in HeLa cells, with DC50 less than 0.1 nM. BRM/BRG1 ligand 4 can be used for the study of cancers associated with SMARCA2/SMARCA4 abnormalities or SWI/SNF mutations .
Cat. No.: HY-184289
Target:
Research Areas:
KJ001-12a is an orally active anti-influenza agent with activity against influenza A and B strains. KJ001-12a acts as an RNA-dependent RNA polymerase inhibitor that reduces the expression levels of viral M2 mRNA and vRNA. KJ001-12a shows low sensitivity to the loss of inhibitory activity caused by the I38T mutation. KJ001-12a is applicable for influenza-related research .
Cat. No.: HY-190685
KRAS G12D-IN-38 is an orally effective KRAS G12D inhibitor. KRAS G12D-IN-38 potently inhibits the proliferation of tumor cells harboring KRAS G12D mutations, with an IC50 of 1.1 nM against AsPC-1 cells. KRAS G12D-IN-38 can be used for research on KRAS G12D-mutant tumors .
Cat. No.: HY-51424R
CAS No.: 918505-84-7
PLX-4720 (Standard) is the analytical standard of PLX-4720. This product is intended for research and analytical applications. PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Cat. No.: HY-P10925
CAS No.: 3044032-95-0
Synonyms: FOG-001; I-66
Cat. No.: HY-P2858H
Target:
Research Areas:
β-Mannosidase, Streptomyces coelicolor (EC 3.2.1.25) catalyses the following chemical reaction:Hydrolysis of terminal, non-reducing beta-D-mannose residues in beta-D-mannosides. This gene encodes a member of the glycosyl hydrolase 2 family. The encoded protein localizes to the lysosome where it is the final exoglycosidase in the pathway for N-linked glycoprotein oligosaccharide catabolism. Mutations in this gene are associated with beta-mannosidosis, a lysosomal storage disease that has a wide spectrum of neurological involvement.
Cat. No.: HY-P4919
CAS No.: 1802078-31-4
Target:
Research Areas:
Cat. No.: HY-P99340A
Synonyms: VIR-7831 (LS); GSK-4182136 (LS)
Sotrovimab (VIR 7831) (LS) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. The Fc region of Sotrovimab (LS) incorporates the M428L and N434S mutations, which are intended to extend its serum half-life. Sotrovimab (LS) could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease [2].
Cat. No.: HY-W814315
CAS No.: 1256577-71-5
Synonyms: CH5424802 analog; RO5424802 analog; RG7853 analog
Target:
Research Areas:
Alectinib analog (CH5424802 analog) is a selective ALK inhibitor with activity in blocking resistance gating mutations. The synthetic optimization of alectinib analog allows it to be combined with specific peptides to improve the ability to target cancer cells. Alectinib analog exhibits low micromolar IC50 values in antiproliferation and shows good cytotoxic effects. The inhibitory activity of alectinib analog is closely related to its stability and release of active ingredients. Alectinib analog demonstrated the ability to inhibit vascular septal length or width in an in vivo zebrafish model .
Cat. No.: HY-122670
CAS No.: 1627962-21-3
VS-II-173 is a pan-Pim kinase inhibitor with IC50 values of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPKα1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC50 > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations [2].
Cat. No.: HY-117081
CAS No.: 457100-08-2
Target:
Fenaminosulf is a plant immune modulator and mutagen. Fenaminosulf impairs plant immune recognition and signal transduction by inhibiting the activities of key kinases such as Xa21 and PBL19, thereby regulating the expression of genes related to hormone metabolism, phenylpropane biosynthesis, and plant-pathogen interactions. Fenaminosulf affects the growth and gall formation of Zizania latifolia in a concentration-dependent manner. Fenaminosulf induces mutations in bacterial systems and causes plant chromosome aberrations, but shows no mutagenic activity or lethal effect in Drosophila melanogaster. Fenaminosulf exhibits inconsistent carcinogenicity in rat studies [2].
Cat. No.: HY-131328R
CAS No.: 2101700-15-4
Synonyms: LOXO-305 (Standard)
Target:
Research Areas:
Pirtobrutinib (Standard) is the analytical standard of Pirtobrutinib (HY-131328). This product is intended for research and analytical applications. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other Kinases tested and shows no significant inhibition of non-Kinase off-targets at 1 μM .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
